Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder
Author:
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Psychiatry and Mental health,Pharmacology
Link
http://academic.oup.com/ijnp/article-pdf/10/5/661/1811652/10-5-661.pdf
Reference58 articles.
1. Interruption of selective serotonin reuptake inhibitor treatment
2. Selective serotonin-reuptake inhibitors: an update
3. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent
4. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects
Cited by 190 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders;JAMA Psychiatry;2024-08-01
2. Agomelatine alleviates steroid‐induced osteoporosis by targeting SIRT1/RANKL/FOXO1/OPG signalling in rats;Clinical and Experimental Pharmacology and Physiology;2023-11-11
3. Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis;Medicine;2023-11-10
4. Comparing the effect of agomelatine and sertraline in treating patients with major depression disorder;INT ARCH HEALTH SCI;2023
5. Latest updates on the serotonergic system in depression and anxiety;Frontiers in Synaptic Neuroscience;2023-05-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3